Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02956122
Recruitment Status : Terminated (The decision to discontinue the study was based on business reasons.)
First Posted : November 7, 2016
Results First Posted : April 24, 2019
Last Update Posted : June 25, 2019
Sponsor:
Collaborator:
Kamada, Ltd.
Information provided by (Responsible Party):
Shire ( Baxalta now part of Shire )

Brief Summary:
The purpose of the study is to evaluate the safety and efficacy of GLASSIA as an add-on biopharmacotherapy to standard-of-care steroid treatment as the first-line treatment in participants with acute GvHD with lower GI involvement.

Condition or disease Intervention/treatment Phase
Graft Versus Host Disease Biological: GLASSIA Drug: methylprednisolone or equivalent steroid Biological: Albumin Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Two-Part, Multi-Center, Prospective, Phase 2/3 Clinical Study to Evaluate the Safety and Efficacy of GLASSIA as an Add-On Biopharmacotherapy to Conventional Steroid Treatment in Subjects With Acute Graft-Versus-Host Disease With Lower Gastrointestinal Involvement
Actual Study Start Date : April 26, 2017
Actual Primary Completion Date : May 3, 2018
Actual Study Completion Date : May 3, 2018


Arm Intervention/treatment
Experimental: Study Part 1 - All Participants - GLASSIA
Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
Biological: GLASSIA
GLASSIA [Alpha1-Proteinase Inhibitor (Human)]
Other Names:
  • as alpha-1 antitrypsin
  • A1PI
  • alpha-1 proteinase inhibitor

Drug: methylprednisolone or equivalent steroid
The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.

Experimental: Study Part 2 - GLASSIA
Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
Biological: GLASSIA
GLASSIA [Alpha1-Proteinase Inhibitor (Human)]
Other Names:
  • as alpha-1 antitrypsin
  • A1PI
  • alpha-1 proteinase inhibitor

Drug: methylprednisolone or equivalent steroid
The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.

Placebo Comparator: Study Part 2 - Albumin (Control)
Participants to receive control (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
Drug: methylprednisolone or equivalent steroid
The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.

Biological: Albumin
The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).
Other Name: Human Albumin




Primary Outcome Measures :
  1. Percentage of Participants Achieving Overall Response (OR) At Day 28 [ Time Frame: Day 28 ]
    OR was defined as graft-versus-host disease (GvHD) complete response (CR) + partial response (PR), defined as: - GvHD CR was complete resolution of all signs and symptoms of acute GvHD in all organs without intervening salvage and GvHD PR was improvement of 1 stage in 1 or more organs involved in GvHD without progression in other organs.


Secondary Outcome Measures :
  1. Percentage of Participants Achieving Gastrointestinal (GI) Response at Day 28 [ Time Frame: Day 28 ]
    GI response was defined as complete response (CR) + partial response (PR), defined as: - GI CR was able to eat; not requiring parenteral nutrition, and passing primarily formed stools - GI PR was decrease in need for parenteral nutrition to less than or equal to (<=) 50% of required calories; and reduction of stool volume by greater than or equal to (>=) 50%, without ileus.

  2. Percentage of Participants Achieving Overall Response at Day 56 [ Time Frame: Day 56 ]
    Overall response was defined as graft-versus-host disease (GvHD) complete response (CR) + partial response (PR), defined as: - GvHD CR was complete resolution of all signs and symptoms of acute GvHD in all organs without intervening salvage - GvHD PR was improvement of 1 stage in 1 or more organs involved in GvHD without progression in other organs.

  3. Acute Graft-versus-host Disease (GvHD) Grading at Days 28, 56 and 180 [ Time Frame: Days 28, 56 and 180 ]
    Grading of GvHD was performed by the investigator according to the modified International Bone Marrow Transplant Registry (IBMTR) grading system which classifies the degree of involvement of each organ system by stage on a scale of 0 to 4. The degree of skin involvement was staged depending upon degree and severity of the lesions: Stage 1: Maculopapular rash over less than (<) 25% of body area, Stage 2: Maculopapular rash over 25 to 50% of body area, Stage 3: Generalized erythroderma, Stage 4: Generalized erythroderma with bullous formation. Degree of GI involvement was staged based on severity of diarrhoea: Stage 1: 500 to 1000 mL/day,Stage 2: 1000 to 1500 mL/day, Stage 3: 1500 to 2000 mL/day, Stage 4: greater than (>) 2000 mL/day OR pain OR ileus. Degree of liver involvement was staged based upon serum total bilirubin level as follows: Stage 1: 2 to 3 mg/dL, Stage 2: 3 to 6 mg/dL, Stage 3: 6 to 15 mg/dL, Stage 4: >15 mg/dL.

  4. Incidence of Chronic Graft-versus-host Disease (GvHD) [ Time Frame: Days 180 and 365 ]
    Incidence of chronic GvHD at Days 180 and 365 was reported.

  5. Duration of Overall Response (OR) [ Time Frame: Baseline up to Day 365 ]
    OR was defined as GvHD CR + PR, defined as: - GvHD CR was complete resolution of all signs and symptoms of acute GvHD in all organs without intervening salvage - GvHD PR was improvement of 1 stage in 1 or more organs involved in GvHD without progression in other organs. Duration of OR was not assessed due to the termination of the study.

  6. Duration of Gastrointestinal (GI) Response [ Time Frame: Baseline up to Day 365 ]
    GI response was defined as CR + PR, defined as: - GI CR was able to eat; not requiring parenteral nutrition, and passing primarily formed stools - GI PR was decrease in need for parenteral nutrition to <= 50% of required calories; and reduction of stool volume by >= 50%, without ileus. Duration of GI response was not assessed due to the termination of the study.

  7. Overall Survival (OS) - Percentage of Participants With an Event [ Time Frame: Days 100, 180 and 365 ]
    OS was defined as the time from the date of randomization to the date of death due to any cause.

  8. Transplant-related Mortality [ Time Frame: Days 28, 56, 100 and 180 ]
    Transplant-related mortality was determined by the investigator (any deaths considered related to the transplant).

  9. Failure-free Survival - Percentage of Participants With an Event [ Time Frame: Days 100 and 180 ]
    Failure-free survival was defined as the absence of all of the following criteria: Need for second-line treatment for acute GvHD, Non-relapse mortality (death during continuous complete remission) and recurrent malignancy.

  10. Graft-versus-host Disease (GvHD)-Free Survival - Percentage of Participants With an Event [ Time Frame: Days 28, 56, 100, 180 and 365 ]
    GVHD-free survival was defined as being alive without previous onset of acute GVHD or chronic GVHD requiring immunosuppressive therapy.

  11. Infection-related Mortality - Percentage of Participants With an Event [ Time Frame: Days 28, 56, 100 and 180 ]
    Infection-related mortality was determined by the investigator (any deaths considered related to infection [including infections related to hematopoietic stem cell transplant {HSCT}]).

  12. Graft-versus-host Disease (GvHD)-Related Mortality - Percentage of Participants With an Event [ Time Frame: Days 28, 56, 100 and 180 ]
    Graft-versus-host disease (GvHD)-related mortality was determined by the investigator (any deaths considered related to GvHD).

  13. All-cause Mortality - Percentage of Participants With an Event [ Time Frame: Days 28, 56, 100 and 180 ]
    All-cause mortality was defined as the time from HSCT to death due to any cause.

  14. Number of Participants With Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs and Temporally-associated AEs [ Time Frame: From start of study drug administration up to 371 days ]
    An AE was defined as any untoward medical occurrence in a participant administered an investigational product (IP) that does not necessarily have a causal relationship with the treatment. An SAE was defined as an untoward medical occurrence that at any dose meets one or more of the following criteria: outcome was fatal/results in death, life-threatening, required inpatient hospitalization or resulted in prolongation of an existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.

  15. Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments [ Time Frame: Baseline up to Day 56 ]
    Clinical laboratory assessments such as hematology, clinical chemistry, lipid and coagulation panels and urinalysis were performed.

  16. Number of Participants With Clinically Significant Changes in Vital Signs [ Time Frame: Baseline up to Day 56 ]
    Vital signs included body temperature, respiratory rate, pulse rate and systolic and diastolic blood pressure.

  17. Number of Participants With Recurrence of Primary Malignancies [ Time Frame: Baseline up to Day 365 ]
    Incidence of recurrence of primary malignancies was reported.

  18. Area Under the Plasma Concentration Curve (AUC0-inf) From Time Zero to Infinity [ Time Frame: Day 1: through 48 hours; Day 13: through 48 hours; Day 22 and Day 50: through approximately 168 hours ]
    AUC of GLASSIA was reported.

  19. Area Under the Plasma Concentration Curve From Time Zero to Time "t" AUC(0-t) of GLASSIA [ Time Frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours ]
    AUC(0-t) of GLASSIA was reported.

  20. Systemic Clearance at Steady State (CLss) of GLASSIA [ Time Frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours ]
    CLss of GLASSIA was reported.

  21. Maximum Observed Plasma Concentration (Cmax) of GLASSIA [ Time Frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours ]
    Cmax of GLASSIA was reported.

  22. Apparent Volume of Distribution at Steady State (Vss) of GLASSIA [ Time Frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours ]
    Vss of GLASSIA was reported.

  23. Apparent Terminal Half-life (t1/2) of GLASSIA [ Time Frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours ]
    Apparent terminal half-life (hour), determined as ln2/lambda-z. lambda-z is the apparent terminal rate constant (one per hour), determined by linear regression of the terminal points of the log-linear concentration-time curve. Visual assessment will be used to identify the terminal linear phase of the concentration-time profile. A minimum of 3 data points will be used for determination. t1/2 of GLASSIA was reported.

  24. Mean Residence Time (MRT) of GLASSIA [ Time Frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours ]
    MRT of GLASSIA was not calculated.

  25. Trough Plasma Concentration at Steady State (Ctrough) of GLASSIA [ Time Frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours ]
    Ctrough of GLASSIA was not assessed due to the termination of the study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female participants aged ≥18 years at the time of screening
  2. Recipient of an hematopoietic stem cell transplantation (HSCT)
  3. The disease indication for which the participant required HSCT must be in remission
  4. Newly diagnosed acute graft-versus-host disease (GvHD), including lower Gastrointestinal (GI) involvement (modified International Bone Marrow Transplant Registry [IBMTR] Severity Stage 1 to 4 [>500 mL diarrhea/day]), with or without other organ system involvement.
  5. Willing to undergo or must have had a lower GI biopsy within 7 days of informed consent to confirm GI GvHD. Biopsy results are not needed to initiate treatment; however, if biopsy results are not consistent with aGvHD, treatment with GLASSIA will be discontinued.
  6. Participants must be receiving systemic corticosteroids. Treatment with methylprednisolone/systemic steroids must have been initiated within 72 hours prior to the first dose of study treatment after enrollment
  7. Evidence of myeloid engraftment (absolute neutrophil count ≥0.5 x 10^9/L)
  8. Lower GI GvHD manifested by diarrhea must have other causes of diarrhea ruled out (eg, negative for Clostridium difficile or cytomegalovirus [CMV] infection or oral magnesium administration)
  9. Karnofsky Performance Score ≥50%
  10. If female of childbearing potential, participant presents with a negative blood pregnancy test
  11. Females of childbearing potential with a fertile male sexual partner must agree to employ adequate contraception for the duration of the study.
  12. Males must use adequate contraception and must not donate sperm for the duration of the study.
  13. Participant is willing and able to comply with the requirements of the protocol

Exclusion Criteria:

  1. Participant with manifestations of chronic GvHD
  2. Participant with acute/chronic GvHD overlap syndrome
  3. Participant whose GvHD developed after donor lymphocyte infusion
  4. Participant with myocardial infarction within 6 months prior to enrollment or New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to the first dose of study treatment, any electrocardiogram (ECG) abnormality at screening must be documented by the investigator as not medically relevant
  5. Participant with evidence of recurrent malignancy
  6. Participant with veno-occlusive disease (ie, sinusoidal obstruction syndrome)
  7. Participant receiving GvHD treatment other than continued prophylaxis (eg, cyclosporine and/or mycophenolate mofetil, etc) or corticosteroid therapy. In addition, a participant who received the first dose of corticosteroid therapy for acute GvHD with lower GI involvement more than 72 hours before the first dose of study treatment is not eligible for the study
  8. Participant with severe sepsis involving at least 1 organ failure
  9. Participant who is seropositive or positive in the nucleic acid test for human immunodeficiency virus (HIV)
  10. Participant with active hepatitis B or C
  11. Participant has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
  12. If female, participant is pregnant or lactating at the time of enrollment, or has plans to become pregnant during the study
  13. Participant with a serious medical or psychiatric illness likely to interfere with participation in the study
  14. Participant is a family member or employee of the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02956122


Locations
Layout table for location information
United States, Georgia
Georgia Cancer Center
Augusta, Georgia, United States, 30912
Sponsors and Collaborators
Baxalta now part of Shire
Kamada, Ltd.
Investigators
Layout table for investigator information
Study Director: Study Director Shire
  Study Documents (Full-Text)

Documents provided by Shire ( Baxalta now part of Shire ):
Study Protocol  [PDF] April 19, 2017
Statistical Analysis Plan  [PDF] September 13, 2017


Layout table for additonal information
Responsible Party: Baxalta now part of Shire
ClinicalTrials.gov Identifier: NCT02956122     History of Changes
Other Study ID Numbers: 471501
First Posted: November 7, 2016    Key Record Dates
Results First Posted: April 24, 2019
Last Update Posted: June 25, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Access Criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
URL: https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Alpha 1-Antitrypsin
Protease Inhibitors
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents
Protective Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Trypsin Inhibitors
Serine Proteinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action